Artículos de revistas
Up-regulation Of Plasminogen Activator Inhibitor-2 Is Associated With High-risk Hpv And Grade Of Cervical Lesion At Baseline But Does Not Predict Outcomes Of High-risk Hpv Infections Or Incident Cin
Registro en:
American Journal Of Clinical Pathology. , v. 132, n. 6, p. 883 - 892, 2009.
29173
10.1309/AJCPQQ07WUTZUTES
2-s2.0-72949087974
Autor
Syrjanen S.
Naud P.
Sarian L.
Derchain S.
Roteli-Martins C.
Longatto-Filho A.
Tatti S.
Branca M.
Erzen M.
Hammes L.S.
Costa S.
Syrjanen K.
Institución
Resumen
Protease inhibitor serpin-B2 (plasminogen activator inhibitor-2 [PAI-2]) protects pRb from degradation in human papillomavirus (HPV)-18+ HeLa cells. Our objective was to assess whether the pRb-mediated HPV-suppressive effect of PAI-2 in cancer cell lines has implications in the outcome of HPV infections. Cervical biopsy specimens from 225 women were analyzed for PAI-2 expression to assess its value as a predictor of cervical intraepithelial neoplasia (CIN) grade, high-risk (HR) HPV at baseline, outcomes of HR-HPV infections, and the development of incident CIN. PAI-2 expression increased in parallel with lesion grade. Nuclear PAI-2 expression was significantly related to HR-HPV detection and had a linear relationship with HR-HPV load. PAI-2 expression was of no value in predicting the outcomes of HR-HPV infections. The same was true for PAI-2 as a predictor of surrogate end points (incident CIN 1+, CIN 2+) of progressive disease. PAI-2 expression is up-regulated on transition from CIN 2 to CIN 3. The HR-HPV suppressive effects of PAI-2 were not related to more favorable outcomes of HR-HPV infections or lower risk of disease progression to CIN. © American Society for Clinical Pathology. 132 6 883 892 zur Hausen, H., Papillomaviruses in the causation of human cancers: A brief historical account (2009) Virology, 384, pp. 260-265 Syrjänen, K.J., Biology of human papillomavirus (HPV) infections and their role in squamous cell carcinogenesis (1987) Med Biol, 65, pp. 21-39 Syrjänen, K., Syrjänen, S., (2000) Papillomavirus Infections in Human Pathology, , New York, NY: Wiley; Syrjänen, S., Syrjänen, K., The history of papillomavirus research (2008) Cent Eur J Public Health, 16 (SUPPL.), pp. S7-S13 Munoz, N., Bosch, F.X., de Sanjose, S., Epidemiologic classification of human papillomavirus types associated with cervical cancer (2003) N Engl J Med, 348, pp. 518-527 Cliffort, G.M., Gallus, S., Herrero, R., Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: Pooled analysis (2005) Lancet, 366, pp. 991-998 Syrjänen, S.M., Syrjänen, K.J., New concepts on the role of human papillomavirus in cell cycle regulation (1999) Ann Med, 31, pp. 175-187 von Knebel Doeberitz, M., New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections (2002) Eur J Cancer, 38, pp. 2229-2242 Munger, K., Baldwin, A., Edwards, K.M., Mechanisms of human papillomavirus-induced oncogenesis (2004) J Virol, 78, pp. 11451-11460 Branca, M., Ciotti, M., Santini, D., p16INK4A expression is related to grade of CIN and high-risk human papillomavirus but does not predict virus clearance after conization or disease outcome (2004) Int J Gynecol Pathol, 23, pp. 354-365 Santopietro, R., Shabalova, I.P., Petrovichev, N., Cell cycle regulators p105, p107, Rb2/p130, E2F4, p21CIP1/WAF1, cyclin-A in predicting CIN, high-risk human papillomavirus infections and their outcome in women screened in three new independent states of the former Soviet Union (2006) Cancer Epidemiol Biomarker Prev, 15, pp. 1250-1256 Du, W., Pogoriler, J., Retinoblastoma family genes (2006) Oncogene, 25, pp. 5190-5200 Chau, B.N., Wang, J.Y., Coordinated regulation of life and death by RB (2003) Nat Rev Cancer, 3, pp. 130-138 Darnell, G.A., Antalis, T.M., Johnstone, R.W., Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif (2003) Mol Cell Biol, 23, pp. 6520-6532 Tonnetti, L., Netzel-Arnett, S., Darnell, G.A., SerpinB2 protection of retinoblastoma protein from calpain enhances tumor cell survival (2008) Cancer Res, 68, pp. 5648-5657 Croucher, D.R., Saunders, D.N., Lobov, S., Revisiting the biological roles of PAI2 (SERPINB2) in cancer (2008) Nat Rev Cancer, 8, pp. 535-545 Myöhänen, H., Vaheri, A., Regulation and interactions in the activation of cell-associated plasminogen (2004) Cell Mol Life Sci, 61, pp. 2840-2858 Belin, D., Biology and facultative secretion of plasminogen activator inhibitor-2 (1992) Thromb Haemost, 70, pp. 144-147 Duffy, M.J., The urokinase plasminogen activator system: Role in malignancy (2004) Curr Pharm Des, 10, pp. 39-49 Croucher, D.R., Saunders, D.N., Stillfried, G.E., A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells (2007) Biochem J, 408, pp. 203-210 Croucher, D., Saunders, D.N., Ranson, M., The urokinase/PAI-2 complex: A new high affinity ligand for the endocytosis receptor low density lipoprotein receptor-related protein (2006) J Biol Chem, 281, pp. 10206-10213 Darnell, G.A., Antalis, T.M., Rose, B.R., Silencing of integrated human papillomavirus type 18 oncogene transcription in cells expressing serpinB2 (2005) J Virol, 79, pp. 4246-4256 Syrjänen, K., Naud, P., Derchain, S.M., Comparing Pap smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America: Study design and baseline data of the LAMS Study (2005) Anticancer Res, 25, pp. 3469-3480 Longatto-Filho, A., Maeda, M.Y.S., Eržen, M., Conventional Pap smear and liquid-based cytology as screening tools in low-resource settings of Latin America: Experience of the Latin American Screening Study (2005) Acta Cytol, 49, pp. 500-506 Sarian, L., Derchain, S.M., Naud, P., Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America: This report refers to partial results from the LAMS (Latin AMerican Screening) study (2005) J Med Screen, 12, pp. 142-149 Longatto-Filho, A., Eržen, M., Branca, M., Human papillomavirus (HPV) testing as an optional screening tool in low-resource settings of Latin America: Experience from the LAMS Study (2006) Int J Gynecol Cancer, 16, pp. 955-962 Syrjänen, K., Shabalova, I., Naud, P., Persistent high-risk human papillomavirus infections and other end-point markers of progressive cervical disease among women prospectively followed up in the New Independent States of the Former Soviet Union and the Latin American Screening study cohorts (2009) Int J Gynecol Cancer, 19, pp. 934-942 Seed, P.T., Tobias, A., Summary statistics for diagnostic tests (2001) Stata Tech Bull, 59, pp. 9-12 Syrjänen, K.J., Summary statement on prognostic factors in carcinoma of the uterine cervix (2003) CME J Gynec Oncol, 8, pp. 298-301 von Knebel-Döberitz, M., Syrjänen, K., Molecular markers: How to apply in practice (2006) Gynecol Oncol, 103, pp. 18-20 Hasina, R., Hulett, K., Bicciato, S., Plasminogen activator inhibitor-2: A molecular biomarker for head and neck cancer progression (2003) Cancer Res, 63, pp. 555-559 Branca, M., Ciotti, M., Giorgi, C., Predicting high-risk human papillomavirus (HPV) infection, progression of cervical intraepithelial neoplasia (CIN) and prognosis of cervical cancer with a panel of 13 biomarkers tested in multivariate modelling (2008) Int J Gynecol Pathol, 27, pp. 265-273 Tan, X., Wang, J.Y., The caspase-Rb connection in cell death (1998) Trends Cell Biol, 8, pp. 116-120 Branca, M., Giorgi, C., Santini, D., Survivin as a marker of cervical intraepithelial neoplasia and high-risk human papillomavirus and a predictor of virus clearance and prognosis in cervical cancer (2005) Am J Clin Pathol, 124, pp. 113-121. , for the HPV-Pathogen ISS Study Group